In Re Axsome Therapeutics, Inc. Stockholder Derivative Litigation

The Delaware Court of Chancery recently issued its opinion in *In Re Axsome Therapeutics, Inc. Stockholder Derivative Litigation*, addressing critical aspects of demand futility in shareholder derivative actions. The consolidated litigation centered on allegations of breaches of fiduciary duty by Axsome's directors related to a significant corporate event, specifically concerning the oversight of a key drug development program and associated regulatory compliance. The Court's decision, while reaffirming the high pleading standard under Court of Chancery Rule 23.1, provided further clarity on the application of the universal demand futility test established in *United Food and Commercial Workers Union and Participating Food Industry Employers Tri-State Pension Fund v. Zuckerberg*. This ruling underscores the robust protections afforded to corporate boards under Delaware law and offers valuable insights for practitioners navigating the complexities of derivative litigation and corporate governance.

The Delaware Court of Chancery, a pivotal forum for corporate disputes, recently rendered its decision in *In Re Axsome Therapeutics, Inc. Stockholder Derivative Litigation*, C.A. No. 2025-1076-LWW, on July 9, 2026. This consolidated shareholder derivative action presented the Court with an opportunity to apply and refine established principles of Delaware corporate law, particularly concerning the demanding pleading requirements for demand futility under Court of Chancery Rule 23.1. The case involved allegations that the board of directors of Axsome Therapeutics, Inc., a biopharmaceutical company focused on central nervous system (CNS) disorders, breached their fiduciary duties in connection with the oversight of a critical drug development program and related regulatory matters.

Shareholder derivative suits are a vital mechanism for holding corporate fiduciaries accountable for harm to the corporation. However, they are subject to stringent procedural hurdles, most notably the requirement that a plaintiff either make a pre-suit demand on the board of directors or plead with particularity why such a demand would be futile. The *Axsome* decision is significant for practitioners as it reinforces the high bar for plaintiffs seeking to bypass the board's authority and provides further guidance on the application of the universal demand futility test, which has been the subject of ongoing judicial development in Delaware. This article will delve into the Court's reasoning, its implications for corporate boards, and the strategic considerations for both plaintiffs and defendants in future derivative litigation.

Delaware law vests the management of a corporation's business and affairs in its board of directors. This fundamental principle, enshrined in Section 141(a) of the Delaware General Corporation Law (DGCL), underpins the demand requirement in derivative litigation. A shareholder bringing a derivative action must comply with Court of Chancery Rule 23.1 (and its federal counterpart, Federal Rule of Civil Procedure 23.1), which mandates that the complaint "allege with particularity the efforts, if any, made by the plaintiff to obtain the action the plaintiff desires from the directors or comparable authority and the reasons for the plaintiff's failure to obtain the action or for not making the effort."

The "demand futility" exception to this rule has been a cornerstone of Delaware corporate jurisprudence, evolving through seminal cases. Initially, the Delaware Supreme Court in *Aronson v. Lewis* established a two-pronged test: demand is excused if particularized facts create a reasonable doubt that (1) the directors are disinterested and independent, or (2) the challenged transaction was the product of a valid business judgment. Later, *Rales v. Blasband* introduced an alternative test for situations where the board did not approve the challenged transaction, or a majority of the board had changed since the transaction, focusing on whether a majority of the current board could exercise independent and disinterested business judgment in responding to a demand. More recently, in *United Food and Commercial Workers Union and Participating Food Industry Employers Tri-State Pension Fund v. Zuckerberg*, the Delaware Supreme Court adopted a universal three-part test, consolidating *Aronson* and *Rales* into a single framework for assessing demand futility. This test requires plaintiffs to plead particularized facts creating a reasonable inference that (1) a majority of the board has a material personal interest in the challenged transaction, (2) a majority of the board lacks independence from someone who has a material personal interest in the challenged transaction, or (3) the challenged transaction was not the product of a valid exercise of business judgment. A critical aspect of derivative claims also includes the duty of oversight, often referred to as *Caremark* duties, which requires directors to implement and monitor a system of internal controls to ensure legal compliance and prevent corporate harm.

In *In Re Axsome Therapeutics, Inc. Stockholder Derivative Litigation*, the plaintiffs alleged that Axsome's board of directors breached their fiduciary duties by failing to adequately oversee the company's development and regulatory approval process for a key pipeline drug, AXS-07, intended for acute migraine. Specifically, the complaint asserted that the board consciously disregarded or utterly failed to implement a reasonable information and reporting system, or, having implemented such a system, failed to monitor it, leading to significant delays and ultimately a Refuse-to-File letter from the U.S. Food and Drug Administration (FDA) due to alleged chemistry, manufacturing, and controls (CMC) deficiencies. This regulatory setback, the plaintiffs contended, caused substantial financial losses and reputational damage to Axsome.

The Court of Chancery, applying the universal demand futility test from *Tri-State Pension Fund v. Zuckerberg*, meticulously examined the plaintiffs' particularized allegations. The plaintiffs attempted to satisfy the second prong of the *Tri-State* test, arguing that a majority of the board faced a substantial likelihood of liability for a *Caremark* breach of the duty of oversight. To succeed on a *Caremark* claim, plaintiffs must demonstrate that the directors either (a) utterly failed to implement any reporting or information system or controls, or (b) having implemented such a system, consciously failed to monitor or oversee its operations, thus disabling themselves from being informed of risks or problems requiring attention.

The Court found that the plaintiffs' complaint, while detailing the adverse regulatory outcome and its financial impact, failed to plead with particularity that a majority of Axsome's directors acted in bad faith or with a conscious disregard of their oversight responsibilities. The Court noted that Axsome's corporate governance guidelines, including an audit committee charter, outlined a framework for board oversight of risk management and compliance. The mere occurrence of a corporate setback, even a significant one, does not automatically give rise to a *Caremark* claim. The Court emphasized that plaintiffs must demonstrate a sustained or systematic failure of the board to exercise oversight, or an utter failure to implement any reporting system, which is a very high standard.

Furthermore, the Court considered the exculpatory provision in Axsome's certificate of incorporation, permitted under DGCL § 102(b)(7), which shields directors from monetary liability for breaches of the duty of care. While *Caremark* claims, if proven, can implicate the duty of loyalty (bad faith), the Court determined that the plaintiffs' allegations, even when viewed in the light most favorable to them, did not rise to the level of bad faith necessary to overcome the exculpatory clause. The complaint lacked specific facts demonstrating that the directors *knew* of the CMC deficiencies and consciously chose to ignore them, rather than merely being negligent in their oversight. The Court reiterated that discovery is generally not available to aid derivative plaintiffs in pleading demand futility, reinforcing the importance of a thorough books and records inspection under DGCL § 220 prior to filing suit.

Ultimately, the Court dismissed the consolidated derivative action for failure to adequately plead demand futility. The decision underscored that the universal demand futility test requires concrete, particularized allegations demonstrating a genuine incapacity of the board to consider a demand impartially, rather than merely alleging corporate mismanagement or poor business outcomes. The Court's analysis reaffirmed the strong presumption of the business judgment rule and the demanding nature of *Caremark* claims, particularly when an exculpatory provision is in place.

The Delaware Court of Chancery's decision in *In Re Axsome Therapeutics, Inc. Stockholder Derivative Litigation* serves as a crucial reminder of the formidable procedural hurdles facing plaintiffs in shareholder derivative actions. For practicing attorneys, the ruling reinforces the imperative of pleading demand futility with extreme particularity, especially when alleging *Caremark* oversight failures. Plaintiffs' counsel must conduct exhaustive pre-suit investigations, often through books and records demands under DGCL § 220, to uncover specific facts demonstrating a board's interestedness, lack of independence, or conscious disregard of its duties, rather than relying on conclusory allegations or hindsight critiques of business decisions.

For corporate boards and their counsel, the *Axsome* decision highlights the continued importance of robust corporate governance structures, comprehensive compliance programs, and diligent board oversight. Boards should ensure that effective information and reporting systems are not only in place but are also actively monitored and regularly reviewed. While the business judgment rule and exculpatory provisions offer significant protection, a sustained or systematic failure of oversight can still expose directors to liability. This ruling reaffirms Delaware's commitment to balancing shareholder protection with the need to shield directors from frivolous litigation, ensuring that derivative suits remain a tool for genuine accountability rather than a means to second-guess ordinary business risks.